Aflac Incorporated generates its revenue primarily through net earned premiums from its supplemental health and life insurance products, supplemented by substantial net investment income from its massive $160 billion investment portfolio. The company’s business model is uniquely bifurcated between its United States operations and its Japanese operations, with Aflac Japan actually generating the majority of the company’s total net earned premiums, often accounting for over 60% of the total premium volume. In the United States, Aflac operates as the dominant provider of supplemental health insurance, offering products such as accident, critical illness, hospital indemnity, and short-term disability insurance. These products are designed to fill the gaps left by major medical insurance, particularly as employers have increasingly shifted to high-deductible health plans that expose employees to significant out-of-pocket costs for deductibles, copayments, and coinsurance. When a policyholder experiences a covered event, such as an accident or a hospital stay, Aflac pays a cash benefit directly to the individual, rather than paying a healthcare provider. This cash can be used for any purpose, whether it is to cover medical bills, pay for household expenses, or replace lost income during a recovery period, a value proposition that has driven the massive growth of the supplemental insurance market over the past two decades. The US distribution model is centered around worksite marketing, where Aflac utilizes a network of over 30,000 independent agents to present their products directly to employees in the workplace, often during open enrollment periods for the company’s major medical plan. This worksite model is incredibly efficient, resulting in a customer acquisition cost that is a fraction of the direct-to-consumer or broker-driven models utilized by competitors, and it benefits from the implicit endorsement of the employer, which drives high participation rates and low policy lapse rates. In Japan, Aflac’s business model is fundamentally different, operating as a top-tier life insurer with a dominant position in the cancer insurance segment. The Japanese national health insurance system covers approximately 70% of medical costs, but patients are still responsible for the remaining 30% out-of-pocket, and cancer treatments often require long-term care, experimental therapies, and lost income that the national system does not fully cover. Aflac Japan pioneered the concept of cash-benefit cancer insurance in the 1970s, offering policies that pay a lump sum or daily cash benefit directly to the policyholder upon diagnosis or hospitalization. This product resonated deeply with the Japanese consumer, allowing Aflac to capture over a 50% market share in the cancer insurance segment and build a massive, highly profitable book of business that generates over $10 billion in annual premiums. The Japanese model relies heavily on a direct sales force and a network of agency shops, rather than the employer-based worksite model used in the US, and it benefits from the cultural emphasis on financial preparedness and the demographic reality of an aging population that is acutely aware of the financial risks associated with cancer. Beyond premium collection, Aflac’s business model is heavily dependent on its investment operations. The company collects billions in premiums upfront and pays out claims over time, creating a massive float that is invested primarily in fixed-income securities, such as corporate bonds, government bonds, and mortgage-backed securities. The net investment income generated from this $160 billion portfolio is a critical component of Aflac’s profitability, often accounting for 20% to 30% of the company’s total pre-tax earnings. In a higher-interest-rate environment, Aflac is able to reinvest maturing bonds and new premium cash flows at higher yields, gradually increasing the overall yield of its portfolio and expanding its net investment income margin. This dual-engine model—underwriting profit from insurance operations and investment profit from the float—creates a highly resilient financial architecture that has allowed Aflac to generate consistent earnings and massive free cash flow, which the company aggressively returns to shareholders through a combination of quarterly dividends and share repurchases. The company’s capital allocation strategy is strictly disciplined, targeting the return of over 100% of its adjusted free cash flow to shareholders, a commitment that has driven a significant reduction in its outstanding share count and consistently supported earnings per share growth, even in years where top-line premium growth is constrained by macroeconomic headwinds or competitive pricing pressures. Aflac’s expense ratio, which measures the cost of running the business relative to its premium volume, is consistently among the lowest in the industry, a testament to the efficiency of its worksite distribution model and its centralized operational infrastructure in Columbus, Georgia. This structural cost advantage allows Aflac to maintain competitive pricing while still generating attractive underwriting margins, creating a formidable barrier to entry for new competitors who lack the scale and distribution efficiency to operate profitably at similar price points. The company’s claims processing operations, which handle over 6 million claims annually, are highly automated and integrated with major healthcare providers and payroll systems, ensuring rapid payment to policyholders and minimizing administrative overhead. This operational excellence, combined with the immense brand equity of the Aflac Duck, creates a powerful retention tool that keeps policy lapses significantly below industry averages, ensuring that the company’s book of business continues to generate recurring premium revenue year after year. Aflac’s business model is not without its risks, particularly its exposure to interest rate fluctuations, healthcare cost inflation, and the demographic shifts in Japan, but its diversified revenue streams, disciplined underwriting, and massive scale provide a level of financial resilience that few competitors can match. The company's ability to cross-sell additional products to its existing policyholder base, particularly in Japan where the lifetime value of a cancer insurance customer can extend for decades, further amplifies the efficiency of its distribution network and maximizes the return on its marketing investments. By maintaining a relentless focus on operational efficiency, actuarial discipline, and strategic capital allocation, Aflac has built a business model that is uniquely positioned to generate sustainable, long-term value for its shareholders, regardless of the broader economic cycle or the competitive dynamics of the global insurance market.